Vor Bio presented novel research on February 13, 2025, at the TANDEM Meetings of ASTCT and CIBMTR, evaluating patient experience and barriers to enrollment and participation in cell and gene therapy (CGT) trials. The data highlighted the need to improve the process for patients considering and enrolling in these complex trials.
The study investigated key barriers by surveying and interviewing 30 physicians, study coordinators, research nurses, and other clinicians, as well as patient advocacy partners. Key findings revealed significant opportunities for institutions and trial sponsors to streamline processes and enroll more patients.
This research will inform Vor Bio’s communications approach for future clinical trials and how the company can support patients and partner institutions through the enrollment process. The findings aim to address the complexity of CGT therapies and help patients better understand their options.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.